This trial is a phase 3 study to evaluate efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.~In Rosuvastatin/Ezetimibe+Telmisartan treatment group, 60 subjects will be assigned and the subjects administer Rosuvastatin/Ezetimibe+Telmisartan for 8 weeks.~In Rosuvastatin/Ezetimibe treatment group, 60 subjects will be assigned and the subjects administer Rosuvastatin/Ezetimibe for 8 weeks.~In Telmisartan treatment group, 60 subjects will be assigned and the subjects administer Telmisartan for 8 weeks.
The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.